BELLOMO, GIOVANNI
 Distribuzione geografica
Continente #
NA - Nord America 365
AS - Asia 230
EU - Europa 190
OC - Oceania 5
SA - Sud America 4
Totale 794
Nazione #
US - Stati Uniti d'America 365
SG - Singapore 104
HK - Hong Kong 77
IT - Italia 64
IE - Irlanda 55
CN - Cina 34
DE - Germania 21
FI - Finlandia 16
RO - Romania 11
JP - Giappone 6
NL - Olanda 5
NZ - Nuova Zelanda 5
VN - Vietnam 5
AT - Austria 4
BR - Brasile 4
FR - Francia 4
RU - Federazione Russa 3
KR - Corea 2
SK - Slovacchia (Repubblica Slovacca) 2
DK - Danimarca 1
HR - Croazia 1
IN - India 1
IS - Islanda 1
MD - Moldavia 1
PT - Portogallo 1
TW - Taiwan 1
Totale 794
Città #
Singapore 87
Chandler 83
Hong Kong 76
Boardman 56
Dublin 55
Santa Clara 31
Perugia 18
San Mateo 18
Altamura 12
Helsinki 11
Timisoara 10
Lawrence 9
Medford 9
Princeton 9
Wilmington 9
Los Angeles 7
Dallas 6
Redmond 6
Tokyo 6
Andover 5
Auckland 5
Dong Ket 5
Falls Church 5
Lappeenranta 5
Rome 5
Milan 4
Des Moines 3
Groningen 3
Nuremberg 3
São Paulo 3
Beijing 2
Brixen 2
Genoa 2
Munich 2
New York 2
Newark 2
Redwood City 2
Seoul 2
Shanghai 2
Vienna 2
Alviano 1
Amsterdam 1
Ann Arbor 1
Anshan 1
Ashburn 1
Bratislava 1
Brookfield 1
Böblingen 1
Changchun 1
Chicago 1
Chisinau 1
Curitiba 1
Düsseldorf 1
Ergolding 1
Fairfield 1
Falkenstein 1
Gunzenhausen 1
Hachenburg 1
Harbin 1
Hengshui 1
Houston 1
Kampong Loyang 1
Lisbon 1
Ma'anshan 1
Mumbai 1
Radeberg 1
Reykjavik 1
Seattle 1
Secaucus 1
Shenzhen 1
Taoyuan 1
Trento 1
Zagreb 1
Zhoukou 1
Zwenkau 1
Totale 619
Nome #
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment 74
A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies 61
Cerebrospinal fluid hemoglobin levels as markers of blood contamination: relevance for α-synuclein measurement 52
Measurement of CSF core Alzheimer disease biomarkers for routine clinical diagnosis: Do fresh vs frozen samples differ? 49
Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimer's Disease 38
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid 38
Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics 34
Identification of natural products able to counteract the formation of advanced glycation end-products (AGEs) sustaining muscle atrophy 33
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview 32
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease 32
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward 31
An unbalanced synaptic transmission: Cause or consequence of the amyloid oligomers neurotoxicity? 29
CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment 28
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 27
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers 25
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 21
LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes 21
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 19
Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD 18
CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 17
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease 17
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay 16
Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias 16
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: Disease staging by NF-L, p-tau181, and GFAP 16
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts 16
Lipoproteins and α-synuclein in cerebrospinal fluid in Parkinson's disease: "Dangerous liaisons" on the road to neurodegeneration? 15
The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis 15
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease 14
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease 12
CSF neurosecretory proteins VGF and neuroserpin in patients with Alzheimer's and Lewy body diseases 8
Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays 4
Research advancement in fluid biomarkers for Parkinson's disease 3
Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers 1
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease 1
Totale 833
Categoria #
all - tutte 5.547
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.547


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202133 0 0 0 4 16 3 0 0 0 0 3 7
2021/202264 1 10 2 0 2 5 4 13 4 7 7 9
2022/2023259 9 60 8 17 19 22 0 20 91 1 8 4
2023/2024223 10 16 12 6 7 1 34 6 49 11 27 44
2024/2025254 7 55 51 37 54 44 6 0 0 0 0 0
Totale 833